Literature DB >> 27431338

Prostate cancer: Testosterone therapy for hypogonadal men with prostate cancer.

Salvatore P Catarinicchia1, E David Crawford1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27431338     DOI： 10.1038/nrurol.2016.118

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

Authors:  Charles Huggins; Clarence V Hodges
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

Review 2.  Risks of testosterone-replacement therapy and recommendations for monitoring.

Authors:  Ernani Luis Rhoden; Abraham Morgentaler
Journal:  N Engl J Med       Date:  2004-01-29       Impact factor: 91.245

3.  Testosterone Therapy in Patients with Treated and Untreated Prostate Cancer: Impact on Oncologic Outcomes.

Authors:  Jesse Ory; Ryan Flannigan; Colin Lundeen; James G Huang; Peter Pommerville; S Larry Goldenberg
Journal:  J Urol       Date:  2016-04-27       Impact factor: 7.450

Review 4.  Testosterone Therapy in Men With Prostate Cancer.

Authors:  Alan L Kaplan; Jim C Hu; Abraham Morgentaler; John P Mulhall; Claude C Schulman; Francesco Montorsi
Journal:  Eur Urol       Date:  2015-12-21       Impact factor: 20.096

5.  Effects of Testosterone Level on Lower Urinary Tract Symptoms.

Authors:  E David Crawford; Wendy Poage; Allen Nyhuis; David A Price; Sherie A Dowsett; David Muram
Journal:  Am J Mens Health       Date:  2015-06-14

6.  Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.

Authors:  Ignacio F San Francisco; Pablo A Rojas; William C DeWolf; Abraham Morgentaler
Journal:  BJU Int       Date:  2014-05-04       Impact factor: 5.588

Review 7.  Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

Authors:  Abraham Morgentaler; Abdulmaged M Traish
Journal:  Eur Urol       Date:  2008-09-24       Impact factor: 20.096

8.  The natural history and predictors of outcome following biochemical relapse in the dose escalation era for prostate cancer patients undergoing definitive external beam radiotherapy.

Authors:  Zachary S Zumsteg; Daniel E Spratt; Paul B Romesser; Xin Pei; Zhigang Zhang; William Polkinghorn; Sean McBride; Marisa Kollmeier; Yoshiya Yamada; Michael J Zelefsky
Journal:  Eur Urol       Date:  2014-10-11       Impact factor: 20.096

9.  Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results.

Authors:  Ravi Kacker; Mariam Hult; Ignacio F San Francisco; William P Conners; Pablo A Rojas; William C Dewolf; Abraham Morgentaler
Journal:  Asian J Androl       Date:  2016 Jan-Feb       Impact factor: 3.285
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.